Xilio Therapeutics, Inc.
XLO Nasdaq
SEC CIK 1840233
Follow Xilio Therapeutics
Weekly email: filings, results
Revenue, last quarter
$10M
−47.6% vs same quarter last year
Net income
−$5.9M
+63.5% vs same quarter last year
EPS, diluted
−$0.30
+81% vs same quarter last year
Operating cash flow
−$13.8M
+21.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$35M |
| FY24 | −$58.2M |
| FY23 | −$76.4M |
| FY22 | −$88.2M |
| FY21 | −$75.8M |
| FY20 | −$55.2M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$5.5M |
| FY24 | −$18.4M |
| FY23 | −$69.1M |
| FY22 | −$77.6M |
| FY21 | −$81.9M |
| FY20 | −$38.3M |
| FY19 | - |